Open AccessIn classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability
Author(s) -
Naike Casagrande,
Cinzia Borghese,
Donatella Aldinucci
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.279389
Subject(s) - maraviroc , ccr5 receptor antagonist , trabectedin , cancer research , lymphoma , stroma , antagonist , medicine , pharmacology , biology , immunology , pathology , chemokine receptor , sarcoma , receptor , chemokine , soft tissue sarcoma , immunohistochemistry , human immunodeficiency virus (hiv)